A randomized controlled trial of lymphoblastoid interferon‐α in patients with chronic hepatitis B lacking HBeAg

Hepatology

Volumn 15, Issue 4, 1992, Pages 584-589

  Fattovich, Giovanna ^a   Farci, Patrizia ^b   Rugge, Massimo ^a   Brollo, Lucio ^a   Mandas, Antonella ^b   Pontisso, Patrizia ^a   Giustina, Giuliano ^a   Lai, M Eliana ^b   Belussi, Fabio ^c   Busatto, Graziella ^a   Balestrieri, Angelo ^b   Ruol, Arturo ^a   Alberti, Alfredo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c Department of Infectious Disease ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LYMPHOBLAST INTERFERON; VIRUS DNA;

ADULT; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; FEVER; HEADACHE; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LIVER FUNCTION TEST; LIVER INJURY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; REMISSION; VIRUS REPLICATION;

ADULT; BIOPSY; CHRONIC DISEASE; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMAN; INTERFERON TYPE II; LIVER; MALE; SUPPORT, NON-U.S. GOV'T;

EID: 0026514922     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.1840150405     Document Type: Article

References (19)

1. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis
2. Clinical, virologic and histological outcome following seroconversion from HBeAg to anti‐HBe in chronic hepatitis type B
3. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen: an active and progressive disease unresponsive to immunosuppressive treatment
4. Hepatitis C virus infection in chronic hepatitis B virus carriers
5. Detection of hepatitis B virus DNA directly in human sera by a simplified molecular hybridization test: comparison to HBeAg/anti‐HBe status in HBsAg carriers
6. Chronic hepatitis in HBsAg carriers with serum HBV‐DNA and anti‐HBe
7. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection
8. Long‐term follow‐up of anti‐HBe positive chronic active hepatitis B
9. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen
10. Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long‐term follow‐up study of 138 patients
11. Acute and chronic hepatitis revisited
12. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
13. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa‐2a by intramuscular injection
14. Natural history and prognostic factors of chronic hepatitis type B
15. A randomized, controlled trial of interferon alfa‐2a alone and after prednisone withdrawal for the treatment of chronic hepatitis B
16. Interferon: immunobiology and clinical significance
17. Interferon alfa‐2b treatment of HBeAg negative/serum HBV‐DNA positive chronic active hepatitis type
18. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection
19. Which patients with chronic hepatitis B virus infection will respond to α‐interferon therapy? A statistical analysis of predictive factors